Skip to main content

Table 3 The differences between survivors and non-survivors

From: Blood purification therapy for severe sepsis: a multicenter, observational cohort study in northern Japan

Variables

Survivors (N = 477)

Non-survivors (N = 139)

p

Unadjusted OR (95% CI)

Age (year)

76 (65–83)

75 (65–84)

0.808

1.001 (0.988–1.014)

Male sex

285/477 (67.6)

94/139 (59.7)

0.093

0.711 (0.477–1.060)

Severity

APACHE II score (0–71)

19 (14–24)

26 (22–33)

 < 0.001

1.112 (1.082–1.142)

SOFA score (0–24)

7 (5–10)

10 (7–13)

 < 0.001

1.215 (1.152–1.282)

Comorbidity

Chronic kidney disease

42/477 (8.8)

19/139 (13.7)

0.091

1.640 (0.920–2.924)

Malignancy

50/477 (10.5)

21/139 (15.1)

0.133

1.520 (0.877–2.631)

Diabetes mellitus

143/477 (30.0)

33/139 (23.7)

0.152

0.727 (0.467–1.126)

Hepatic disease

17/477 (3.6)

5/139 (3.6)

0.985

0.985 (0.366- 2.787)

Others

180/477 (37.7)

49/139 (35.3)

0.594

0.903 (0.612–1.333)

Physiological variables (day 1)

Worst GCS score

14 (10–15)

11 (6–14)

 < 0.001

0.863 (0.824–0.905)

Worst heart rate (beats/min)

111 (95–126)

119 (102–131)

0.030

1.006 (0.998–1.014)

Worst mean arterial pressure (mmHg)

66.7 (56.0–86.0)

59.3 (46.7–73.7)

 < 0.001

0.979 (0.969–0.989)

Lactate level (mg/dL)

24.3 (17.1–37.8)

30.6 (18.8–62.3)

 < 0.001

1.015 (1.009–1.021)

PaO2:FiO2

243.5 (148.4–333.3)

180.6 (94.6–312.5)

 < 0.001

0.997 (0.996–0.999)

Worst creatinine level (mg/dL)

1.2 (0.8–2.0)

1.6 (1.0–2.9)

 < 0.001

1.083 (0.983–1.194)

Bilirubin level (mg/dL)

0.9 (0.6–1.5)

1.0 (0.6–1.5)

0.379

1.055 (0.983–1.194)

Platelet count (cells × 104/mm3)

16.4 (10.8–23.4)

14.2 (7.9–22.4)

0.020

0.981 (0.962–1.000)

AKI-related variables (day 1–3)

AKI

167/477 (35.0)

91/139 (65.5)

 < 0.001

3.519 (2.366–5.235)

AKI stage

 0

310/477 (65.0)

48/139 (34.5)

 < 0.001

1.000

 1

48/477 (10.1)

15/139 (10.8)

 

2.018 (1.049–3.884)

 2

41/477 (8.6)

16/139 (11.5)

 

2.520 (1.312–4.842)

 3

78/477 (16.4)

60/139 (43.2)

 

4.968 (3.157–7.819)

Primary site of infection

  

 < 0.001

 

Lung

147/477 (30.8)

70/139 (50.4)

 

1.000

Urinary tract

155/477 (32.5)

29/139 (20.9)

 

0.210 (0.100–0.441)

Abdomen

90/477 (18.9)

9/139 (6.5)

 

0.393 (0.241–0.640)

Others

84/477 (17.8)

31/139 (22.3)

 

0.766 (0.464–1.263)

Blood purification therapy

Any BPT

72/475 (15.2)

38/139 (34.5)

 < 0.001

2.952 (1.920–4.540)

Any CRRT

63/475 (13.3)

44/139 (31.7)

 < 0.001

3.029 (1.941–4.727)

CRRT for renal indications

42/474 (8.9)

40/139 (28.8)

 < 0.001

4.156 (2.559–6.750)

CRRT for non-renal indications

26/473 (5.5)

7/139 (5.0)

0.833

0.912 (0.387–2.148)

IRRT

19/474 (4.0)

9/137 (6.6)

0.207

1.684 (0.744–3.812)

PMX-DHP

24/473 (5.1)

18/138 (13.0)

0.005

2.806 (1.475–5.340)

Other therapies

Mechanical ventilation within 24 h

190/474 (40.1)

91/138 (65.9)

 < 0.001

2.894 (1.946–4.305)

Inotropes or vasopressors

218/472 (46.2)

94/138 (68.1)

 < 0.001

2.489 (1.667–3.718)

Antimicrobial therapy

458/462 (99.1)

132/134 (98.5)

0.522

0.576 (0.104–3.182)

Drainage or operation

178/474 (29.1)

43/138 (31.2)

0.169

1.329 (0.886–1.993)

  1. Data are expressed as medians (interquartile ranges) for continuous variables and numbers (%) for categorical variables
  2. The Wilcoxon rank sum test was used for the continuous variables, and the Chi-square test was used for categorical variables
  3. Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were analyzed using a univariable logistic regression model
  4. APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, GCS Glasgow Coma Scale, AKI acute kidney injury, BPT blood purification therapy, CRRT continuous renal replacement therapy, IRRT intermittent renal replacement therapy, PMX-DHP polymyxin B immobilized fiber column-direct hemoperfusion
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us